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 KEY MESSAGES  
What is the key question? Which health-related quality of life questionnaires are used in 
bronchiectasis and what is the evidence for their validity? 
What is the bottom line? Despite differences in the construct of frequently used 
questionnaires St George’s Respiratory Questionnaire, Leicester Cough Questionnaire and 
Quality of Life - Bronchiectasis, there is good evidence to support their validity, internal 
reliability and repeatability.  
Why read on? This article provides an in depth review of the evidence for the validity of 
HRQOL questionnaires and their association with commonly used clinical outcome 
parameters; this may help investigators to select the most appropriate tool for their purpose. 
 LIST OF ABBREVIATIONS: 
CAT  Chronic Obstructive Pulmonary Disease Assessment Tool  
CI  Confidence Intervals 
COPD  Chronic Obstructive Pulmonary Disease 
CQLQ  Cough Quality of Life Questionnaire  
CRDQ  Chronic Respiratory Disease Questionnaire 
CT  Computed Tomography 
EuroQOL Euro Quality of Life 
HRQOL Health-Related Quality of Life 
ICC  Intraclass Correlation Coefficient 
QOL-B Quality of Life - Bronchiectasis 
LCQ  Leicester Cough Questionnaire 
SF-36  Medical Outcomes Study 36-item Short-Form Health Survey  
SGRQ  St George’s Respiratory Questionnaire 
SNOT-20 20-Item Sino-Nasal Outcome Test  
 ABSTRACT 
Background: Health-related quality of life (HRQOL) is impaired in bronchiectasis. A range 
of HRQOL questionnaires have been used to assess HRQOL in bronchiectasis. A systematic 
review was conducted to evaluate the psychometric properties of these questionnaires. This 
included a meta-analysis to assess associations between HRQOL and clinical measures.   
Methods: Five electronic databases were searched. Studies eligible for inclusion were those 
that investigated the validity of HRQOL questionnaires and/or their association with other 
outcomes in adults with bronchiectasis. Patients with cystic fibrosis were excluded. The 
identified questionnaires were assessed for convergent, discriminant and cross-cultural 
translation validity; missing data, floor and ceiling effects, internal consistency and test-retest 
reliability. A meta-analysis was conducted to estimate the strength of associations between 
HRQOL and clinical measures. 
Results: From 1,918 studies identified, 43 studies were included in the systematic review, of 
which 38 were suitable for the meta-analysis. Nine HRQOL questionnaires were identified, 
with the most widely used being: St George’s Respiratory Questionnaire, Leicester Cough 
Questionnaire, Quality of Life - Bronchiectasis and Short Form 36. HRQOL questionnaires 
had moderate to good internal consistency and good test-retest reliability. Only 8 of 18 
studies that used translated HRQOL questionnaires reported or referred to the validity of the 
translated questionnaire. There was a stronger correlation between HRQOL and subjective 
outcome measures, such as cough (r=0.57), dyspnoea (r=0.55) and fatigue (r=0.42) compared 
to objective measures; exercise capacity (r=-0.41), FEV1% predicted (r=-0.31) and extent of 
bronchiectasis in computed tomography scan (r=0.35); all p<0.001. 
Conclusions: This review supports most HRQOL questionnaires used in bronchiectasis have 
good psychometric properties. There was a weak to moderate association between HRQOL 
 and objective outcome measures. This supports that HRQOL questionnaires assess a unique 
aspect of health not captured by objective measures. 
Abstract word count: 250 
  
INTRODUCTION 
The assessment of health-related quality of life (HRQOL) is important in chronic disease as it 
evaluates the overall impact on health from the patients’ perspective. Bronchiectasis is a 
persistent or progressive condition characterised by dilated thick-walled bronchi.1 Symptoms 
of bronchiectasis include sputum production, cough, haemoptysis, dyspnoea and fatigue, 
which are worse during exacerbations. HRQOL is impaired in bronchiectasis.2 A range of 
tools have been used to assess HRQOL in bronchiectasis. These include generic tools such as 
the Medical Outcomes Study 36-Short-form Health Survey (SF-36), organ-specific tools such 
as the St George’s Respiratory Questionnaire (SGRQ) and Leicester Cough Questionnaire 
(LCQ) and the condition-specific Quality of Life – Bronchiectasis (QOL-B).3-6 The 
comparative validity of HRQOL questionnaires used to assess bronchiectasis has not been 
investigated; such a review may inform investigators and clinicians about the choice of 
HRQOL questionnaires available and their validity. The aim of this systematic literature 
review was to evaluate the psychometric properties of questionnaires used to assess HRQOL 
in bronchiectasis. This included a meta-analysis to assess the associations of HRQOL with 
other clinical measures.  
 
METHODS 
Study eligibility criteria 
The inclusion criteria were: empirical studies of adult patients (16 years old) with 
bronchiectasis, studies reporting the psychometric properties of generic and disease specific 
HRQOL questionnaires, and/or the association of HRQOL with other clinical measures. The 
diagnosis of bronchiectasis was established using clinical and/or radiological features. The 
 review was limited to studies reporting in English language. Studies investigating acute 
exacerbations were included if they met the inclusion criteria. Studies investigating mixed 
populations such as adult/paediatric and non-cystic fibrosis/cystic fibrosis bronchiectasis were 
included if the findings reported were distinguishable by age/disease category. The exclusion 
criteria were: diagnosis of cystic fibrosis and review articles (used only to identify further 
references). Clinical trials that did not investigate HRQOL psychometric properties as their 
primary purpose were excluded. Studies using cognitive interview or focus group 
methodology that did not include HRQOL questionnaires were also excluded.  
 
The psychometric properties considered included convergent and discriminant validity 
(relationship with other clinical measures according to expectations), internal consistency (α 
Cronbach’s coefficient: extent to which the items of a questionnaire are interrelated), test-
retest reliability (repeatability during a clinically stable period), missing data, floor (minimum 
score) and ceiling (maximum score) effects. The validity of translated HRQOL 
questionnaires was evaluated by assessing if forward/backward translation, cognitive 
interviews, internal consistency and reliability was reported. For the purposes of this review 
we refer to the following definition of HRQOL: “the perception of the impact of health on an 
individual’s contentment or satisfaction with life in areas they consider important”.7 
 
Search strategy and terms 
PRISMA guidelines and SIGN methodology checklist for systematic reviews and meta-
analyses were used.8,9 The search was conducted in 5 electronic databases: Embase (1974 to 
2014), Pubmed, Medline (Ovid, 1946 to 2014), PsycINFO (1806 to 2014) and Cochrane 
Library. The keywords for search were: non cystic fibrosis bronchiectasis/bronchiectasis, 
quality of life/QOL/HRQOL, health status, well-being, daily living, questionnaire, 
 validation/validity, psychology and psychometrics. The date of search was the 6th November 
2014. The bibliographies from all included manuscripts were used to identify further 
references. Abstracts with adequate information about study methods and results were 
considered for inclusion. 
 
Study selection, data extraction and quality assessment 
After duplicate references were removed, two reviewers independently assessed the studies 
(in abstract form) against the inclusion criteria. When there was insufficient information 
available in the abstract, the full text was reviewed. Discrepancies between the reviewers were 
resolved through discussion and consensus. Two investigators then extracted data from the 
selected studies including: author, year of publication, aim of the study, sample size, most 
common aetiology of bronchiectasis, age, gender, FEV1% predicted, HRQOL questionnaire 
used and psychometric properties of HRQOL questionnaire including correlation of HRQOL 
with other clinical measures. Clinical measures used for convergent and discriminant validity 
of HRQOL included those that assessed symptoms, anxiety, depression, exercise capacity, 
lung function and other physiological parameters and markers of disease severity and 
infection/exacerbation. The quality of studies was assessed using a critical appraisal tool 
developed by Swigris et al and modified for bronchiectasis (online supplement Appendix 1).7 
Where translated questionnaires were used, the translation procedure was assessed by 
evaluating the included study and related references for forward-backward translation, 
cognitive interviews, floor and ceiling effects, internal consistency and test-retest reliability.   
 
Statistical analysis 
Quantitative analysis was performed with Stata 12.0 (StataCorp LP, Texas) and MetaWin 2.0 
(Baker Hughes Incorporated, Houston). Internal consistency was reported as Cronbach’s α 
 coefficient (acceptable if >0.7) and test-retest reliability as intraclass correlation coefficient 
(ICC) (moderate if =0.5-0.7 and good if >0.7). Meta-analysis was performed to evaluate the 
association between HRQOL and clinical measures when data was available from at least two 
studies. When multiple questionnaires were used to assess HRQOL in the same study, the 
most relevant to bronchiectasis questionnaire was used in the meta-analysis. When total score 
was not available, the mean of the domain scores was used. When the same data were 
repeated in multiple publications, the meta-analysis included the publication with the largest 
sample size that best met the inclusion criteria.  
 
Correlation coefficients were extracted from the studies when available. The strength of 
association was categorised as following: weak r <0.4, moderate r=0.4-0.7 and strong >0.7; 
significance p<0.05). When only p-values and other metrics (t-values, Cohen’s d, F values, 
chi-square values) were available, correlation coefficients were obtained according to 
formulas suggested by Rosenthal et al.10 The correlation coefficients were converted to 
Fisher’s Z using ( )( ) rrl nz −+=
− 1121  and subjected to meta-analytic models.11 For the 
final interpretation of the findings, a mean r correlation coefficient for associations was 
calculated from Fisher’s Z as per . A random effects model was used 
to produce a pooled estimate of the correlation coefficients. Statistical heterogeneity was 
assessed using Cochran’s Q test, which examines the null hypothesis that all studies are 
evaluating the same effect.12 Statistical significance for heterogeneity was set as p≤0.10. 
Heterogeneity was quantified using the I2 statistic, indicating the percentage of total variation 
across studies that is due to heterogeneity rather than chance.12 I2 value of 0% was considered 
to indicate no observed heterogeneity whilst a value >50% substantial heterogeneity.13-15   
 
 Publication bias was assessed using funnel plots and Rosenthal’s fail-safe Number 
(Rosenthal’s N).16 A funnel plot was created for the clinical measures with more than 10 
studies.17 This is a scatter plot of the effect estimates from individual studies against a 
measurement of the study’s sample size or precision. Resemblance of a symmetrical inverted 
funnel supports that findings are due to sampling variation alone; thus absence of bias.18 For 
the funnel plots indicating publication bias, an Engel’s test was performed (null hypothesis: 
studies are no subject to publication bias, significance p<0.05). Rosenthal’s N expresses the 
number of un-retrieved or negative studies that are needed to overturn the results of the meta-
analysis and create a non-significant meta-analytic result.  
 
RESULTS 
Study characteristics 
Study selection  
The search retrieved 1,918 publications (online supplement Table E1). Two additional 
abstracts and a full manuscript were added manually from searching these references.19-21 A 
PRISMA flowchart illustrates the studies selection process and reasons for exclusion (Figure 
1). Forty-three studies met the inclusion criteria for systematic review, of which 38 were 
included in the meta-analysis of associations between HRQOL and other clinical measures. 
Studies with multiple publications were combined and considered as single publications. Five 
studies had subjects who overlapped with those in other publications. 
Overview of included studies & study quality 
The objectives of the included studies are presented in Table 1. All studies were prospective. 
They all reported cross-sectional findings apart from one,22 whilst 9 studies also included 
 longitudinal findings for the investigation of repeatability of the HRQOL questionnaires.4-
6,20,23-27 The studies met a mean (SD) of 48 (14) % of the quality criteria; range 17-78% 
(Figure 2). No study met the criteria for all quality domains. 
Characteristics of patients 
Table 1 presents the clinical characteristics of patients. The studies included a total number of 
3,727 patients with bronchiectasis (median number of bronchiectasis patients per study 98, 
range 6-608). The mean study patient age was 59 (range 43-70) years and 64 (range 37-83) % 
of the patients were female. Three studies recruited participants also during an 
exacerbation,28-30 whilst all remaining studies recruited patients during a clinically stable 
phase.  
 
Health-related quality of life questionnaires 
Overview of health-related quality of life questionnaires 
Seven organ/disease-specific and 2 generic HRQOL questionnaires were identified in the 
selected studies (Table 1). Fifteen studies administered multiple HRQOL questionnaires. 
Twenty-seven studies used the SGRQ, 9 the LCQ, 8 the SF-36, 6 the QOL-B Versions 2.0 or 
3.0, 2 the Chronic Respiratory Disease Questionnaire (CRDQ), 2 the generic Euro Quality of 
Life (EuroQOL) and 1 each of the COPD Assessment Tool (CAT), 20-Item Sino-Nasal 
Outcome Test (SNOT-20) and Cough Quality of Life Questionnaire (CQLQ). A description 
of these HRQOL questionnaires is given in online supplement Appendix 2. All 
questionnaires were originally developed in English language. A summary of average 
HRQOL scores from studies where available is presented in online supplement Table E1.  
 
Validity of translated questionnaires 
 Eighteen studies used a translated HRQOL questionnaire. Translated SGRQ was used in 
Spain,24,31,32 Italy,31 France,31 Belgium,31 Korea,33 Netherlands,30 Mexico,34 Egypt,35 China,36 
Hong Kong,23 and Israel;37 QOL-B in Italy, Belgium, Spain, France and Netherlands;38 LCQ 
in Spain,27 Belgium,39 Netherlands30 and Turkey;40 SF-36 in Spain,32,41 Netherlands,30 and 
Brazil;3 and CAT in Korea.33 Eight out of 18 studies reported or referenced a validation of the 
translated questionnaire. The validation of translated HRQOL questionnaires has been 
reported for: SGRQ in Mexican,34 Hong Kong Chinese,23 Chinese36 and Korean,33 LCQ in 
Spanish,24 Dutch42 and Turkish,43 QOL-B in all aforementioned languages;44 and SF-36 in 
Spanish32,41 and Portuguese Brazilian.45 These studies validated the translated questionnaires 
in patients with bronchiectasis, with only exceptions being the Korean SGRQ (range of 
chronic respiratory diseases);33 Dutch and Turkish LCQ (chronic cough)42,43 and the Brazilian 
SF-36 (COPD and rheumatoid arthritis).45 One study used factor analysis to demonstrate that 
the structure of the translated Spanish questionnaire was similar to the original SGRQ.46  
Floor/ceiling effects and missing data 
Floor and ceiling effects and missing data were reported for only 2 HRQOL questionnaires, 
SGRQ and QOL-B. The floor and ceiling effects for SGRQ in English and Spanish versions 
were small for all domains (<3%).4,46 The floor effect for SGRQ Hong-Kong Chinese was 
<6.4% (activity domain 11.7%) and ceiling effect <1.1%.23 English and Spanish QOL-B floor 
effect ranged from 0% to 5.1%, with the exceptions of vitality (7.2%) and physical and social 
functioning (both 6.4%). The ceiling effects ranged from 0% to 13.5% with exceptions of 
domains: treatment burden ≤17.4%, social and role functioning ≤21.7%, and emotional 
functioning ≤24.1%.5,27,38 Martinez-Garcia et al and Chan et al reported missing data for 
SGRQ domains with a range 2.0-7.9% and 1.3-7.2% respectively.23,46 Quittner et al also 
 reported minimal missing data for QOL-B for all domains with the exception of treatment 
burden (up to 8.7%).5,38 
Internal consistency 
Cronbach’s α coefficients for the HRQOL questionnaires ranged from moderate to high 
(Table 2). The LCQ had the highest internal consistency (Cronbach’s α coefficient 0.91-
0.94).20 QOL-B Cronbach’s α coefficients ranged from 0.65 to 0.96,5,19,26,27 SGRQ from 0.59 
to 0.92,4,23,46 SF-36 from 0.75 to 0.9141 and CAT was 0.84.33 The internal consistency of 
other questionnaires was not reported.  
Test-retest reliability  
Test-retest reliability data was available for SGRQ, QOL-B and LCQ. ICC was moderate to 
high (Table 2). The SGRQ was slightly more repeatable over 2 weeks than the QOL-B (ICC 
range 0.89-0.97 vs. 0.67-0.88 respectively).4,5,19,23,27,38 The LCQ was highly repeatable over 6 
months (ICC=0.96).6 
Associations between health-related quality of life questionnaires 
Several studies reported the strength of association between HRQOL questionnaires. The 
correlation coefficients ranged from weak to strong. The SGRQ total score correlated with 
CAT,31 SNOT-20 and LCQ6,20 (r=0.72, r=0.72 and ρ=-0.70 respectively, all p<0.01). SGRQ 
total correlated weakly to moderately with SF-36 Physical (range r=-0.35 to -0.68, p<0.01)4,23 
and QOL-B V2.0/V3.0 (range r=-0.34 to -0.81, p<0.01).5,19,27 The LCQ correlated strongly 
with SGRQ (ρ=-0.70, p<0.01) and CQLQ (r=-0.88, p<0.001)47 and moderately with CRDQ 
total (r=0.51, p<0.01)47 and EuroQOL (r=0.52 to 0.67, p<0.001).48 The correlation between 
QOL-B domains and EuroQOL was weak to moderate (r=0.29 to 0.66, p<0.001). 
 Discriminant ability of health-related quality of life questionnaires 
SGRQ was reported to be able to discriminate subjects based on the severity of dyspnoea4,46 
and wheeze,4 sputum volume,23,46 CT scan extent of bronchiectasis,49 exacerbation 
frequency,4,31,46 presence of sputum colonisation by Pseudomonas Aeruginosa,46 history of 
haemoptysis in past year27 and the bronchiectasis severity index.31 SGRQ total scores were 
able to discriminate FEV1% categories.
46 There were conflicting data for the discriminative 
ability of the QOL-B for impairment in FEV1%. The number of QOL-B domains able to 
discriminate patients on the basis of FEV1% ranged from 1 to all 8 domains.
5,27,38 QOL-B was 
however reported to be able to discriminate patients according to CT scan extent of 
bronchiectasis27 and sputum Pseudomonas and Haemophilus Influenza colonisation. 
 
Associations between health-related quality of life and clinical measures: a meta-
analysis 
The associations between HRQOL and other clinical measures (convergent/discriminant 
validity) reported in studies were evaluated in a meta-analysis (Table 3). The associations for 
clinical measures where only single studies were available are presented in online supplement 
Table E3. A wide range of associations between HRQOL and clinical measures were reported 
(Figures 3-6 and online supplement Figures E1-E14). The strongest associations of HRQOL 
were with respiratory symptoms such as cough (Figure 3), dyspnoea (Figure 4) and fatigue 
(online supplement Figure E2) and for objective measures with exercise capacity (Figure 5), 
where there were moderate correlations. There was a weak association between HRQOL and 
sputum volume (online supplement Figure E4) and microbiological colonisation (online 
supplement Figure E13), lung function (Figure 6), exacerbation rate (online supplement 
Figure E10) and extent of bronchiectasis on CT scans (online supplement Figure E6). 
 Analysis of publication bias & heterogeneity 
Publication bias was assessed with a funnel plot for FEV1% predicted and exercise capacity as 
these were parameters with ≥10 studies available (online supplement Figures E15 and E16). 
FEV1% resembled a symmetric image, suggesting no publication bias. Exercise capacity 
funnel had slight asymmetry suggesting possibility of publication bias. However, this was not 
confirmed with Enger’s test (p=0.189).  
 
DISCUSSION 
This is the first systematic review of the psychometric properties of HRQOL questionnaires 
used to assess bronchiectasis. The review included 43 studies that investigated 3,727 patients. 
Nine HRQOL questionnaires were identified; the most widely used were the SGRQ and the 
LCQ. One bronchiectasis-specific questionnaire was identified, the recently published QOL-
B. Most HRQOL questionnaires had good internal consistency, test-retest reliability and 
convergent validity. As expected, there was a stronger association between HRQOL and 
subjective outcome measures, compared to objective outcome measures, such as FEV1. This 
suggests that HRQOL questionnaires capture a unique aspect of the illness. 
 
The strongest association of HRQOL was, unsurprisingly, with respiratory symptoms. The 
best association was with cough, a key symptom of bronchiectasis, in the acute and chronic 
phase of illness. There were also significant associations with dyspnoea and wheeze. It 
should be noted that only 2 studies reported the association with cough and wheeze, in 
contrast to 7 studies for dyspnoea. The review also highlights a potentially important 
association between HRQOL and fatigue. Fatigue is an recognised symptom of 
bronchiectasis but its mechanism is poorly understood.40 There was a moderate association 
 between HRQOL and symptoms of depression, and a weaker association with anxiety. There 
was a poor association between HRQOL and frequency of acute exacerbations. This may be 
because HRQOL was assessed in a stable phase in most studies. Another explanation may be 
the variability of the definitions of exacerbation used by investigators. The difficulty in 
defining and reporting exacerbations is well recognised.50 There was no association between 
the presence of co-morbidities and HRQOL. This finding is expected because the HRQOL 
questionnaires used in studies where co-morbidities were reported were the respiratory 
condition-specific tools SGRQ and QOL-B. 
 
We found a poor association between HRQOL and objective measures of bronchiectasis. The 
best association of all objective measures identified was with exercise capacity, such as the 
six-minute walk test. This is not surprising, since measures of exercise capacity are more 
likely to relate to functional ability than other objective disease outcome measures. This may 
be of importance for studies investigating the effects of pulmonary rehabilitation. Our 
findings highlight the discordance between patient-reported outcome measures and 
physiological measures. There was a poor relationship with lung function measure, FEV1. 
This is a widely used outcome measure of bronchiectasis. The poor association with HRQOL 
is consistent with that reported for other chronic respiratory disorders, such as COPD, 
interstitial lung disease and chronic cough.51-53 There were also weaker associations between 
HRQOL and the extent of bronchiectasis on CT scan, and sputum measures such as volume, 
colour and bacterial colonisation. Our data suggests that HRQOL questionnaires assess a 
unique dimension of health, which is distinct from that assessed by objective measures. 
HRQOL measures should ideally complement objective clinical measures in the assessment 
of bronchiectasis.    
 
 Our systematic review suggests that the questionnaires identified generally had good 
psychometric properties required to assess HRQOL. We used criteria similar to those defined 
by McHorley et al to assess psychometric properties.54 The SGRQ was the most widely 
studied questionnaire. The SGRQ was initially developed for COPD and asthma,55 but has 
subsequently been validated and used in a wide range of respiratory disorders. The next most 
commonly used tool was the LCQ, which was initially developed for patients with chronic 
cough,52 but has subsequently been validated in patients with bronchiectasis.6 The QOL-B, a 
recently published questionnaire was the only questionnaire developed specifically for 
bronchiectasis.5 The internal consistency and test-retest reliability was generally good for 
questionnaires studied. The convergent validity was as expected, with a stronger relationship 
with subjective outcome measures compared to objective measures. The responsiveness of 
HRQOL questionnaires and their minimal important difference is another important measure 
of validity. This was beyond the scope of this systematic review, and was therefore not 
investigated. A review of longitudinal studies of HRQOL questionnaires in bronchiectasis is 
needed to assess responsiveness of tools. 
 
Eighteen of the 43 studies used translated questionnaires, in 14 languages. It is essential that 
HRQOL questionnaires are translated and validated using well-recognised and standardised 
procedures to ensure that they are appropriately adapted to accommodate cultural 
differences.56 This procedure includes forward and backward translations, patient interviews, 
pilot testing and demonstration of internal reliability. Whilst there were good examples of 
translated HRQOL questionnaire validity in bronchiectasis, there were many studies where 
this procedure was either not conducted or reported. The validity of translated questionnaires 
was best reported for the LCQ and QOL-B, compared to the SGRQ. It is likely that the 
 translation and validity of the SGRQ may have been performed elsewhere and not reported or 
referenced within the studies identified in this systematic review. 
 
Our systematic review and meta-analysis identified a range of HRQOL questionnaires used 
to assess bronchiectasis. There was a wide variation in the number of items in questionnaires. 
For respiratory-specific HRQOL questionnaires, this ranged from 19 items for the LCQ to 50 
items for the SGRQ. The QOL-B, a bronchiectasis-specific HRQOL questionnaire, has 37 
items, divided into 8 domains. This questionnaire does not have a total score. All 
questionnaires, with the exception of the QOL-B, were not developed in bronchiectasis. 
However, some have subsequently been validated in a bronchiectasis patient population, such 
as the LCQ and SGRQ.4,6 An advantage of the QOL-B is that its’ items are likely to be more 
focused and relevant for patients with bronchiectasis. Furthermore, the QOL-B is likely to be 
more sensitive to change or responsive because it is a condition-specific tool. A large 
proportion of the validation of the QOL-B was conducted in patients with positive sputum 
cultures; therefore the performance of this questionnaire should be evaluated in patients 
unselected for sputum microbiology. In this systematic review, HRQOL questionnaires only 
correlated moderately with each other, which suggests there are differences in the health 
domains assessed and multiple questionnaires may be necessary in some studies to assess 
HRQOL. The floor and ceiling effects of questionnaires were seldom reported, but when 
reported this effect was minimal, which is desirable for HRQOL questionnaires. The 
exception to this was ceiling effects with the QOL-B reported in one study, up to 24%.38 The 
amount of missing HRQOL data was only presented for the SGRQ and QOL-B, and this was 
reasonably low, within a range between 1.3-7.9% and 0-8.7% of items respectively. There 
were some differences in the psychometric properties between HRQOL questionnaires, but 
these were relatively small. The internal consistency was good for all questionnaires; the 
 Cronbach’s α coefficient was highest for the LCQ. The re-test reliability was high for the 
LCQ and SGRQ and variable for QOL-B domains, ranging from moderate to good. The 
convergent validity was also variable for the clinical measures studied. The association with 
exercise capacity was marginally better with SGRQ and LCQ questionnaires compared to 
QOL-B. The association between HRQOL with FEV1 was generally weak, irrespective of the 
questionnaire administered. The association with symptoms of dyspnoea was stronger with 
the SGRQ compared to the QOL-B. It is possible that the differences in psychometric 
properties may reflect differences in the study population, disease characteristics and 
methodology undertaken. Studies that directly compare HRQOL questionnaires are needed to 
establish similarities and differences between questionnaires with confidence.     
 
There are some limitations with our systematic review. Only English-language studies were 
included. Our review is susceptible to publication bias (positive findings are more likely to be 
published compared to negative findings) and time lag bias (inability to identify ongoing or 
unpublished studies), as any review article. Our systematic review and meta-analysis did 
however involve a comprehensive literature search, which led to the identification of 43 
studies for inclusion. We did not contact the study authors to retrieve unpublished data, 
which may lead to over-interpretation of associations between HRQOL and clinical 
measures. We chose to limit the review to those studies specifically evaluating the 
psychometric properties of HRQOL questionnaires and associations with clinical measures. 
We did not include clinical trials as these studies did not specifically evaluate psychometric 
validity of questionnaires and this was also beyond the scope of our review. The data 
available for our systematic review was insufficiently powered to allow assessment of 
individual clinical outcome measures, for example 6 minute walk test vs. shuttle walk test 
used to assess exercise capacity. For the purpose of analysis, we grouped clinical measures 
 together. We therefore may have underestimated important associations due to the 
heterogeneity of clinical outcome measures. Similarly, we assessed some HRQOL 
associations by pooling all available HRQOL questionnaires, as there was insufficient data 
for individual questionnaires. Other potential sources for heterogeneity found in some of the 
meta-analyses were differences in inclusion/exclusion criteria, population and disease 
aetiology. 
 
The quality of HRQOL data and its reporting varied between studies. The 43 studies met an 
average of 48% of the quality criteria assessed. This is very similar to a systematic review of 
HRQOL in idiopathic pulmonary fibrosis.7 A greater proportion of studies met quality criteria 
relating to description of patient demographics, the reporting of major clinical outcome 
measures of bronchiectasis and the analysis of HRQOL data. Fewer studies met the criteria 
for reporting details of the administration of the HRQOL questionnaires and missing data. It 
is therefore possible that the quality of studies and the reporting of data may have 
compromised some of our findings. A greater clarity for reporting HRQOL data is required in 
future studies that include the rationale for choosing a particular instrument, mode of 
administration, details of missing data and sample size estimates.  
 
Our review highlights the questionnaire options available (including translated 
questionnaires), differences in the size and format of questionnaires and also provides an 
indication of the relative psychometric properties of questionnaires. The SGRQ, LCQ, QOL-
B and SF-36 are the most studied HRQOL questionnaires in bronchiectasis. The SGRQ is a 
good choice for a research study if extensive experience of using a HRQOL questionnaire is 
important. The SGRQ also has good psychometric validity. The disadvantage is that it is a 
long questionnaire and potentially may not be as responsive to change as disease specific 
 tools; this requires further study. The LCQ is brief, well validated in bronchiectasis and may 
be particularly advantageous if the symptom of cough is a primary focus. The QOL-B is the 
only disease specific questionnaire and has good psychometric properties. The disadvantage 
of the QOL-B is that it is relatively long and does not have a total score for ease of 
interpretation of data. The SF-36 may be useful in comparative studies that include non-
pulmonary chronic disorders, as it is a generic tool. It is however a relatively long 
questionnaire and is not as extensively validated in bronchiectasis as some of the alternatives. 
Future studies need to provide details of HRQOL questionnaire performance characteristics, 
such as the distribution of data, floor and ceiling effects and missing data. There is a need to 
investigate HRQOL in longitudinal studies, and establish the minimal important difference 
for many tools used in bronchiectasis. There is also a need for briefer tools with simplified 
scoring (ideally inclusive of a total score) for use in the clinical and research setting. HRQOL 
questionnaires should be used to measure the efficacy of therapeutic interventions since they 
assess the patient’s perspective and this should be done in combination with objective 
outcome measures. 
 
In conclusion, we identified 43 studies that evaluated the psychometric properties of 9 
HRQOL questionnaires, and their association with clinical measures. Translated HRQOL 
questionnaires should be developed using standardised procedures and appropriately 
validated. This should be reported or referenced. Most HRQOL questionnaires used in 
bronchiectasis had good psychometric properties. There were some differences between 
questionnaires in their association with clinical measures. Investigators should select the 
questionnaires for their study based on ease of administration, and those that correlate best 
with the health domain under investigation. More research is needed to investigate 
 longitudinal changes in HRQOL and establish the minimal important differences of 
instruments.  
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Table 1. Characteristics of studies included in the literature review.  
Author 1st, year HRQOL tools Country N Age 
(yr) 
Female 
(%) 
FEV1% 
(pred) 
Most common 
bronchiectasis 
aetiology (%) 
Relevant study objectives 
Wilson, 1997a4 & 
O’Leary, 200257 
SGRQ, SF36 UK 111 52  60 66.4  Idiopathic  58 Validate SGRQ in bronchiectasis.  
Relationship between HRQOL, anxiety and depression. 
Wilson, 1997b49 
& Wilson, 199858 
SGRQ, SF36 UK 87 54 56      63.8 Idiopathic  63 Relationship between HRQOL, sputum bacteriology 
and systemic inflammatory markers. 
Chan, 200223 SGRQ, SF36 HK 93 59 66 73.5 Idiopathic  81 Validate Hong Kong Chinese version of SGRQ. 
Martinez-Garcia, 
2005a2 & 2005b46 
SGRQ ES 102 70 37 60.4 Idiopathic  44 Validate SGRQ in bronchiectasis. 
Relationship between HRQOL and clinical outcomes.  
Eshed, 200737 SGRQ IL 46 63 54 72.3  NR Relationship between SGRQ and CT scores. 
Tomkinson, 
200921   
SGRQ UK 6 *59 83 *50.5  NR Relationship between HRQOL and exercise capacity. 
Guilemany, 
200932 
SGRQ, SF36, 
SNOT-20 
ES 80 57 71 80.8  NR Relationship between HRQOL and chronic 
rhinosinusitis. 
Lee, 200959 SGRQ, SF36  AU 27 54 59 73.9 Post-infective 47 Relationship between HRQOL and exercise capacity. 
Shoemark, 201160 SGRQ UK 53 57 71 *82.1 NR Relationship between HRQOL and exhaled nitric 
oxide. 
Gale, 201061 SGRQ UK 20 *65 80 67.8 NR Relationship between HRQOL, fatigue, balance and 
self-reported physical activity. 
Batchelor, 201162 SGRQ UK 31 59 81 NR  Post-infective 48 Relationship between HRQOL, exacerbation frequency, 
depression, fatigue and lung function. 
Chalmers, 201431 SGRQ UK, BE, IT 608 65 60 69.3 Idiopathic & 
Post-infective  
63 Relationship between HRQOL and Bronchiectasis 
Severity Index. 
Galindo, 201334 SGRQ MX 19 NR 74 NR CVID 100 Relationship between HRQOL and sex. 
Oliveira, 2014a63 
& 2014b27 
QOL-B(V3.0), 
SGRQ 
ES 207 57 63 68.3 Post-infective 39 Validate QOL-B (V3.0) in Spanish.  
Relationship between HRQOL, anxiety and depression. 
Loebinger, 200922 SGRQ UK 91 52 58 65.8 Idiopathic  56 Relationship between HRQOL and mortality risk. 
Lee, 201233 CAT, SGRQ KR 62 61 53 67.3  NR Validate the Korean CAT in bronchiectasis. 
Moreno, 201324 SGRQ ES 70 64 69 74.0  Idiopathic  46 Relationship between HRQOL, anxiety and depression. 
Rowan, 201464  SGRQ UK 60 62 70 76.5 Idiopathic  43 Relationship between HRQOL and lung clearance 
index. 
Gao, 201436 SGRQ CN 144 46 62 67.4 Idiopathic & 
Post-infective  
71 Relationship between HRQOL and quality of sleep. 
Morsi, 201435 SGRQ EG 33 43 55 32.9 NR Relationship between HRQOL, anxiety and depression 
and other clinical measures. 
Murray, 2009b28 SGRQ UK 32 69 63 66.5 ABPA 34 Investigate the HRQOL as an end-point for assessing 
treatment 
 Author 1st, year HRQOL tools Country N Age 
(yr) 
Female 
(%) 
FEV1% 
(pred) 
Most common 
bronchiectasis 
aetiology (%) 
Relevant study objectives 
Guilemany, 
200641 
SF36 ES 60 52 65 81.0 NR Relationship between HRQOL, nasal symptoms and 
polyposis. 
Jacques, 20123 SF36 BR 70 55 69 44.9 Idiopathic 46 Relationship between HRQOL and exercise capacity.  
Polley, 200848 LCQ, CQLQ, 
EuroQOL 
UK 26 58 50 73.2 NR Relationship among different HRQOL questionnaires. 
Ozalp, 201240 LCQ TR 20 44 50 62.5 NR Relationship between HRQOL and dyspnoea, exercise 
capacity, fatigue. 
Murray, 2009a6 & 
2009c65 
LCQ, SGRQ UK 141 68 64 74.0 Post-infective 53 Relationship between HRQOL and sputum colour. 
Validate the LCQ in bronchiectasis. 
Munoz, 201320 LCQ, SGRQ ES 259 58  NR NR  NR Validate LCQ Spanish version in bronchiectasis. 
Altenburg, 201430 LCQ, SGRQ, 
SF-36  
NL 60 67 58 82.3 Idiopathic 50 Relationship between HRQOL and lower respiratory 
tract infections visual analogue score. 
Goeminne, 201439 LCQ BE 63 59 57 69.0 Idiopathic 27 Relationship between HRQOL, lung function and 
inflammatory markers. 
Torrego, 200666 LCQ UK 22 59 82 82.9 NR Relationship between HRQOL and cough reflex. 
Mandal, 201367 LCQ UK 163 66 60 75.0 Idiopathic  58 Relationship between HRQOL and airway reflux. 
Quittner, 2010b19 QOL-B US 35 65 57 57.1 NR Develop and validate the QOL-B. 
Quittner, 2010a26 QOL-B, 
SGRQ 
US 79 63 68 60.2 NR Validate the QOL-B. 
McCullough, 
201168 
QOL-B UK 71 65 69 60.0 NR Relationship between HRQOL, clinical and 
demographic factors. 
Quittner, 20145 QOL-B, 
SGRQ 
US 89 64 70 60.4 NR Develop and validate the QOL-B (V2.0 & V3.0). 
Quittner, 201538  QOL-B, 
SGRQ, 
EuroQOL 
US, CA, 
UK, AU, 
FR, NL, IT, 
ES, BE 
542 64 69 63.0 NR Validate the QOL-B (V3.0). 
Lee, 201047 CRDQ, LCQ AU 27 64 NR 70.0 NR Relationship between CRDQ, LCQ and exercise 
capacity. 
Courtney, 200829 CRDQ UK 18 *54 67 58.1 Post-infective  83 Investigate the impact of physiology and inflammation 
in changes of HRQOL. 
Data presented as means unless otherwise stated. Studies presented on the same row were combined for meta-analysis.  
*: Median. AU: Australia, BE: Belgium, BR: Brazil, CA: Canada, CN: China, CVID: Common Variable Immunodeficiency, EG: Egypt, ES: Spain, FR: 
France, HK: Hong-Kong, IL: Israel, IT: Italy, KR: Korea, MX: Mexico, NL: Netherlands, TR: Turkey, UK: United Kingdom. ABPA: Allergic 
Bronchopulmonary Aspergillosis, CAT: Chronic Obstructive Pulmonary Disease Assessment Tool, CRDQ: Chronic Respiratory Questionnaire, EuroQOL: 
Euro Quality of Life, HRQOL: Health Related Quality of Life, LCQ: Leicester Cough Questionnaire, NR: not reported, SF-36: Short Form 36, SGRQ: St 
George’s Respiratory Questionnaire, SNOT-20: Sinonasal Outcome Test-20, QOL-B: Quality of Life - Bronchiectasis. 
 Table 2. Internal consistency and test-retest reliability of health-related quality of life 
questionnaires in non-cystic fibrosis bronchiectasis. 
Author, year HRQOL 
questionnaire 
Internal consistency Test-retest reliability 
Domain                      Cronbach’s α    Domain                         ICC  
Wilson, 19974 SGRQ Total 
Symptoms     
Activity          
Impact            
NR 
0.90 
 0.89 
0.92 
Total                              
Symptoms                   
Activity 
Impact     
0.97  
0.93                          
  0.98 
0.94                    
Martinez-Garcia, 200546 SGRQ 
 
Total              
Symptoms     
Activity          
Impact            
0.90 
0.81 
0.87 
0.81 
Total 
Symptoms 
Activity 
Impact 
NR 
NR 
NR 
NR 
Chan, 200223 SGRQ 
 
Total               
Symptoms     
Activity          
Impact            
0.92 
0.59 
0.91 
0.88 
Total  
Symptoms 
Activity  
Impact  
0.93 
0.94 
0.84 
0.89 
Quittner, 2010b26 QOL-B 8 domains          (range) 0.65-0.94 8 domains  (range) 0.72-0.88 
Quittner, 2010a19 QOL-B 8 domains  (range) 0.73-0.96 8 domains NR 
Quittner, 20145 QOL-B V3.0* Physical functioning 
Role functioning 
Vitality 
Emotional functioning 
Social functioning 
Treatment burden 
Health perceptions 
Respiratory symptoms  
0.94 
0.86 
0.85 
0.72 
0.66 
0.84 
0.77 
0.82 
Physical functioning  
Role functioning            
Vitality                          
Emotional functioning 
Social functioning         
Treatment burden         
Health perceptions        
Respiratory symptoms  
0.88 
0.84 
0.67 
0.82 
0.85 
0.76 
0.78 
0.80 
Quittner, 201538 QOL-B V3.0 Physical functioning 
Role functioning 
Vitality 
Emotional functioning 
Social functioning 
Treatment burden 
Health perceptions 
Respiratory symptoms  
0.91 
0.84 
0.73 
0.83 
0.77 
0.78 
0.77 
0.81 
Physical functioning 
Role functioning 
Vitality 
Emotional functioning 
Social functioning 
Treatment burden 
Health perceptions 
Respiratory symptoms  
0.85 
0.86 
0.74 
0.79 
0.80 
0.76 
0.76 
0.83 
Olveira, 201427 QOL-B V3.0 Physical functioning  
Role functioning  
Vitality  
Emotional functioning  
Social functioning  
Treatment burden  
Health perceptions  
Respiratory symptoms  
0.91 
0.84 
0.82 
0.84 
0.70 
0.72 
0.71 
0.87 
Physical functioning  
Role functioning  
Vitality  
Emotional functioning  
Social functioning  
Treatment burden  
Health perceptions  
Respiratory symptoms  
0.88 
0.86 
0.78 
0.86 
0.78 
0.68 
0.83 
0.83 
Murray, 20096 LCQ Total                
Physical          
Psychological  
Social               
NR 
NR 
NR 
NR 
Total 
Physical 
Psychological 
Social  
0.96 
NR 
NR 
NR 
Munoz, 201320 LCQ Total                
Physical          
Psychological  
Social               
0.91 
0.94 
0.93 
0.93 
Total                
Physical          
Psychological  
Social 
NR 
NR 
NR 
NR 
Lee, 201233 CAT Total               0.84 Total NR 
Guilemany, 200641 SF36 8 domains (range) 0.75-0.91  NR 
 Cronbach’s α coefficient >0.7 is considered acceptable for HRQOL questionnaires. 
CAT: Chronic Obstructive Pulmonary Disease Assessment Tool, HRQOL: Health-Related Quality of 
Life, ICC: Intraclass Correlation Coefficient, LCQ: Leicester Cough Questionnaire, NR: not reported, 
SGRQ: St George’s Respiratory Questionnaire, QOL-B: Quality of Life - Bronchiectasis. 
*: The repeatability of Quality of Life - Bronchiectasis Version 3.0 was not reported. Table presents 
data from Quality of Life - Bronchiectasis Version 2.0.5 
 Table 3. Meta-analysis: correlations reported for health-related quality of life with clinical measures. 
 
Clinical Measures K N Meta-analysis correlation 
mean r (95% CI) 
Q test I2 (%) 
Rosenthal’s 
N 
Cough 2 124 0.57 (-0.03,   0.87);  p=0.060 7.56; p=0.006 86.8‡    20#  
Dyspnoea 7 1216 0.55  ( 0.41,   0.68);    p=0.000 54.42;    p=0.000 89.0‡  792  
Wheeze 2 213 0.42  ( 0.30,   0.53);    p=0.000 0.27;    p=0.602   0.0    29  
Fatigue 4 182 0.42  ( 0.23,  0.58);    p=0.000 4.72;    p=0.194 36.4    40  
Exercise capacity 11 1038 -0.41  (-0.54,  -0.24);    p=0.000 50.81;    p=0.000 80.3‡  419  
Depression 7 572 0.41  ( 0.23,   0.55);    p=0.000 27.53;    p=0.000 78.2‡  220  
Sputum volume 3 402 0.36  ( 0.24,   0.47);    p=0.000 3.39;    p=0.184 41.0     57  
Pseudomonas presence/colonisation 2 189 0.36  ( 0.23,   0.48);    p=0.000  0.70;    p=0.401   0.0     18#  
CT bronchiectasis scores 10 1880 0.35  ( 0.05,   0.58);    p=0.002 340.27;    p=0.000 97.4‡ 1037  
Oxygen saturation 4 324 -0.35  (-0.44,  -0.24);    p=0.000 0.46;    p=0.928   0.0     51  
Anxiety 5 514 0.34  ( 0.19,   0.47);    p=0.025 11.38;    p=0.023 64.9†     97  
Hospital admissions rate 2 695 0.34  ( 0.16,  0.49); p=0.000 2.95; p=0.086 66.1†     55  
FEV1 % 17 2228 -0.31  (-0.40,  -0.23);    p=0.000 59.32;    p=0.000 73.0†   990  
Infections/exacerbations rate 8 1498 0.31  ( 0.24,   0.38);    p=0.001 12.99;    p=0.072 46.1   380  
FVC % 7 1031 -0.29  (-0.39,  -0.19);    p=0.000 14.39;    p=0.026 58.3†   182  
Any microbiological presence/colonisation 3 758 0.26  ( 0.19,  0.33);  p=0.000 0.43; p=0.805   0.0     43  
Sputum colour 2 204 0.25  ( 0.05,  0.43); p=0.013 1.91; p=0.167 47.6       7#  
Comorbidities 2 815 0.09  ( 0.02,  0.16); p=0.014 0.44; p=0.508   0.0       3#  
 
CI: confidence intervals, CT: computed tomography, FVC%: forced vital capacity percent predicted, FEV1%: forced expiratory volume in the first second 
percent predicted, K: number of studies, N: number of overall participants, r: correlation coefficient. 
For the purposes of comparison, higher score indicates poorer health-related quality of life. 
Statistical heterogeneity among the studies was assessed using the Q test and quantified using the I2. 
Q: Cochran’s Q test, which examines the null hypothesis that all studies are evaluating the same effect. 
I2: Indicates the percentage of total variation across studies that is due to heterogeneity rather than chance. I2 value of 0% was considered to indicate no 
observed heterogeneity. †: I2 between 30-60% may represent moderate heterogeneity among the studies according to Cochrane manual; ‡: I2 between 75-
100% may represent considerable heterogeneity.  
#: Rosenthal’s Number lower than 5*knumber_of_studies + 10 indicates publication bias of the studies included in the meta-analysis. 
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Figure 1. PRISMA flow chart of the literature review and meta-analysis selection process. 
HRQOL, health-related quality of life. 
  
 
 
 
Figure 2. Estimated quality of reporting for included studies.  
x axis: number of studies meeting each quality criterion (total n=43), y axis: quality criterion 
item. Number of total evaluable studies 43 except where indicated as*.  
CF, cystic fibrosis; CT, computed tomography; HRQOL, health-related quality of life; 
HRQOL-Q, health-related quality of life questionnaire. 
  
  
 
Figure 3. Forest plot for the correlation between health-related quality of life and dyspnoea. 
Measurements of dyspnoea used: Medical Research Council (MRC) scale (Wilson et al, 
1997; Martinez-Garcia et al, 2005; Lee et al, 2012; Chalmers et al, 2014; Oliveira et al, 
2014), 12-point Borg scale (Chan et al, 2002) and dyspnoea-12 (Morsi et al, 2014).  
Zero line: is illustrated to indicate the direction of association. A fisher’s z value >0 indicates 
positive association between the two variables. A fisher’s z value <0 indicates negative 
association between the two variables. High score = poor health-related quality of life. 
Dashed line: represents the overall meta-analytic mean Z. Arrow: indicates confidence 
interval limit. Weight was calculated using the inverse variance weight formula 
[weight=i/sqrt(n-3)]. 
 
  
 
Figure 4. Forest plot for the correlation between health-related quality of life and exercise 
capacity. Measurements of exercise capacity used: 6-minute walk test for all studies apart 
from one that used incremental shuttle walk test (Wilson et al, 1997) and another that used 
both (Lee et al, 2010).  
High score = poor health-related quality of life. 
 
  
  
 
Figure 5. Forest plot for the correlation between health-related quality of life and cough. 
Measurements of cough used: cough reflex sensitivity to capsaicin (Torrego et al, 2006) and 
patient-reported cough frequency (Martinez-Garcia et al, 2005). 
 
 
 
 
 
 
 
 
  
  
Figure 6. Forest plot for the correlation between health-related quality of life and FEV1% 
predicted.  
High score = poor health-related quality of life. 
